4VI Stock Overview
Researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Genomtec S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł1.93 |
52 Week High | zł3.35 |
52 Week Low | zł1.78 |
Beta | 0.42 |
11 Month Change | -8.22% |
3 Month Change | -18.99% |
1 Year Change | 8.54% |
33 Year Change | -14.89% |
5 Year Change | n/a |
Change since IPO | -25.55% |
Recent News & Updates
Recent updates
Shareholder Returns
4VI | DE Biotechs | DE Market | |
---|---|---|---|
7D | -2.1% | -0.03% | 2.6% |
1Y | 8.5% | -21.7% | 4.3% |
Return vs Industry: 4VI exceeded the German Biotechs industry which returned -21.7% over the past year.
Return vs Market: 4VI exceeded the German Market which returned 4.3% over the past year.
Price Volatility
4VI volatility | |
---|---|
4VI Average Weekly Movement | 5.0% |
Biotechs Industry Average Movement | 6.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.1% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 4VI's share price has been volatile over the past 3 months.
Volatility Over Time: 4VI's weekly volatility has decreased from 11% to 5% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 17 | Miron Tokarski | www.genomtec.com |
Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus.
Genomtec S.A. Fundamentals Summary
4VI fundamental statistics | |
---|---|
Market cap | €28.82m |
Earnings (TTM) | -€2.24m |
Revenue (TTM) | n/a |
-1,385x
P/S Ratio-12.8x
P/E RatioIs 4VI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4VI income statement (TTM) | |
---|---|
Revenue | -zł89.00k |
Cost of Revenue | zł1.18m |
Gross Profit | -zł1.27m |
Other Expenses | zł8.32m |
Earnings | -zł9.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 27, 2024
Earnings per share (EPS) | -0.72 |
Gross Margin | 1,430.34% |
Net Profit Margin | 10,777.53% |
Debt/Equity Ratio | 7.0% |
How did 4VI perform over the long term?
See historical performance and comparison